Export: +91 9820402906   Domestic: +91 7710003340 | HR: +91 9137757219
Glimepiride Tablets

Glimepiride Tablets

Compositions: Glimepiride IP 1 mg and 2 mg; Glimepiride BP 1 mg, 2 mg and 4 mg; SMEGLIP-1 and SMEGLIP-2.

Separate combination: Glimepiride 2 mg + Pioglitazone 15 mg + Metformin Hydrochloride 500 mg SR.

Usage: Management of type 2 diabetes alongside diet and exercise.

Category: Anti Diabetic Drugs

Therapeutic Category: Antidiabetic

SKU: Glimepiride Tablets

Categories: Pharmaceutical Exporter India, Pharmaceutical Formulations India, WHO GMP Certified Formulations

Product Information

Glimepiride Tablets is listed in our pharmaceutical product portfolio for business-to-business enquiries. Product-specific formulation details, available strengths, dosage form, pack configuration and supply terms should be confirmed against the current product specification before ordering.

For distributor, wholesaler, hospital procurement and export enquiries, please request the applicable product specifications, batch documentation, shelf-life information, packaging options and regulatory documents. Availability and documentation depend on the product and destination market.

Description

Glimepiride Tablets (1 mg / 2 mg / 4 mg)

Manufactured by: Healthy Life Pharma Pvt. Ltd. (WHO-GMP Certified)
Exported by: Healthy Inc (Star Export House)

1. Product Introduction

Glimepiride is an oral sulfonylurea antidiabetic medicine used to improve glycaemic control in adults with type 2 diabetes alongside diet and exercise. Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as the exporter. The confirmed standalone products are film-coated glimepiride 1 mg, 2 mg and 4 mg tablets under the IP/BP standards shown below.

The separately supplied glimepiride/pioglitazone/metformin SR product is a different three-ingredient formulation, not a strength of glimepiride-only tablets.

2. Product Specifications

Generic name: Glimepiride; CAS: 93479-97-1; Therapeutic class: Sulfonylurea antidiabetic; Dosage form: Film-coated tablet for confirmed standalone variants.

Product / brandEach tablet containsDosage form
Glimepiride Tablets IP 1 mgGlimepiride IP 1 mgFilm-coated
Glimepiride Tablets IP 2 mgGlimepiride IP 2 mgFilm-coated
Glimepiride Tablets BP 1 mgGlimepiride BP 1 mgFilm-coated
Glimepiride Tablets BP 2 mgGlimepiride BP 2 mgFilm-coated
Glimepiride Tablets BP 4 mgGlimepiride BP 4 mgFilm-coated
SMEGLIP-1Glimepiride BP 1 mg; excipients q.s.Film-coated
SMEGLIP-2Glimepiride BP 2 mg; excipients q.s.Film-coated
Separate triple combinationGlimepiride 2 mg + Pioglitazone 15 mg + Metformin Hydrochloride 500 mg; excipients q.s.Sustained-release

Strength verification: 3 mg is mentioned in the proposed description but no 3 mg composition was supplied. Shelf life, packaging, tablet colour and exact pharmacopeial test limits must follow the registered product specification.

3. Manufacturing Technology

Manufacturing low-dose glimepiride tablets requires validated blending, tablet-weight control and content uniformity. Particle-size management and dissolution performance are relevant formulation considerations; specific micronization, granulation and colour-coding methods must be verified against the approved manufacturing dossier before being claimed for this product.

4. Quality Assurance

Appropriate quality controls include identification, assay, uniformity of dosage units, dissolution, related substances, packaging integrity and stability testing according to the applicable approved IP/BP specification. Do not assume fixed dissolution percentages or bioequivalence without batch or study documentation.

5. Pharmacology and Clinical Use

Glimepiride binds to sulfonylurea receptors associated with ATP-sensitive potassium channels in pancreatic beta cells, stimulating insulin secretion. It can reduce blood glucose even when glucose is already low and therefore carries a clinically important risk of hypoglycaemia. It is used in type 2 diabetes, alone or with other treatments as prescribed; it is not indicated for type 1 diabetes or diabetic ketoacidosis.

6. Export and Regulatory Support

For export enquiries, product-specific certificates of analysis, packaging options, certificates and CTD/ACTD documentation should be confirmed for the relevant market and registered formulation. Regulatory approval in any country must not be assumed.

7. Frequently Asked Questions

What strengths are documented?
Film-coated 1 mg and 2 mg IP/BP tablets, plus BP 4 mg, SMEGLIP-1 and SMEGLIP-2. A 3 mg formulation is not confirmed by the supplied compositions.

Is Glimepiride the same as Amaryl?
Amaryl is a brand of glimepiride. Pharmaceutical equivalence or bioequivalence for a particular product must be established separately.

Can it cause low blood sugar?
Yes, particularly with missed meals, strenuous exercise, alcohol, illness or interacting medicines.

Is the triple combination the same medicine?
No. It additionally contains pioglitazone and metformin and has separate prescribing precautions.

8. Dosage and Administration

Use the exact dose and timing prescribed by a clinician, typically with breakfast or the first main meal. Dosing depends on blood-glucose monitoring, kidney/liver function, other medicines and the approved label. Do not change dose or substitute combination tablets without medical advice.

9. Side Effects and Precautions

  • Hypoglycaemia: May cause sweating, shaking, hunger, dizziness, confusion or loss of consciousness; urgent treatment may be required.
  • Other effects: Nausea, dizziness and weight gain may occur.
  • Special populations: Older or malnourished patients and those with kidney or liver problems may be more susceptible to prolonged hypoglycaemia.
  • Other cautions: Review hypersensitivity, G6PD deficiency, alcohol use and interacting medications with a clinician.
  • Triple combination: Pioglitazone can cause fluid retention and worsen heart failure; metformin has renal-function precautions and a rare lactic-acidosis risk.

10. Storage Instructions

Store according to the approved pack label, protected from moisture and excessive heat. Keep out of reach of children.